Delhi High Court, responding to pleas from drug companies, quashed the ban on Thursday, saying the Centre had not followed certain procedures such as consulting the Drugs Technical Advisory Board. The consortium, in a statement today, said all the 344 fixed-dose combinations were irrational. Irrational combinations expose patients to unnecessary drugs and therefore to their adverse effects, and increase their expenses. Yet, the consortium said, the fixed-dose combinations represent nearly 40 per cent of India's pharmaceutical market. "None of the 344 irrational FDCs find mention in standard medical textbooks.

Source: The Telegraph December 03, 2016 21:08 UTC